MRK · News · 20260805N

Competition and Market Share

Merck & Co., Inc. · 2026-08-05 · Importance 58 · Surprise 42

Dr. Reddy’s launched first-to-market U.S. generic versions of sugammadex injection, directly competing with Merck’s Bridion. The products are available in 200 mg/2 mL and 500 mg/5 mL single-dose vials and target hospitals and surgical centers using sugammadex to reverse neuromuscular blockade. Bridion had approximately $1.6 billion in U.S. sales, indicating a material potential market-share and pricing threat to Merck’s product.

Key facts

• JPMorgan raised its price target on Merck to $150 from $140 and maintained an Overweight rating. source
• Goldman Sachs adjusted its price target on Merck to $140 from $137 and maintained a Buy rating. source